Fwd: HIV Treatment Bulletin Volume 4 No 3 April 2002

[Guest guest]

see forwarded newsletter from the UK

Vergel

Program for Wellness Restoration, PoWeR

An All Volunteer Non-Profit 501 © 3 Corporation

Don't Lose Your Body to HIV, click here

Facial Reconstructive Procedures

Click to subscribe to lipodystrophy

"A wise man should consider that health is the greatest of human blessings, and learn how by his own thought to derive benefit from his illnesses".

Hippocrates (460 BC - 377 BC), Regimen in Health

Dear HTB subscribers,

Attached is the April 2003 issue of HTB as a PDF file. This months copy

includes articles on;

SPECIAL ISSUE: Reports from the 10th Conference on Retroviruses and

Opportunistic Infections, Boston

EDITORIAL

CONFERENCE REPORTS: 10th Conference on Retroviruses and Opportunistic

Infections (CROI)

CROI: ANTIRETROVIRALS

· Pipeline compounds in phase 2/3 studies

· 96-week results show tenofovir-including regimen has side-effect

advantages over d4T in treatment naïve patients

• 2NN results – nevirapine and efavirenz in prospective randomised

head-to-head study

• NIH/NIAID study of generic drugs shows results consistent with stringent

manufacturing standards

CROI: TREATMENT STRATEGIES

• Treatment interruptions: cycles, pauses, or just plain stopping?

CROI: WOMENS STUDIES

• Conference has strong emphasis on women

CROI: SIDE EFFECTS

• Tenofovir and renal tubular dysfunction

• Approaches to treatment of lipodystrophy

• Surgery for buffalo hump shows variable results depending on method

• Other studies – nucleosides and switching to abacavir; importance of

lipoatrophy and buffalo hump

• HAART to HEART: cardiovascular risk in HIV

• Alendronate, vitamin D and calcium are safe and effective treatment for

HIV-associated bone loss

• Bone loss and fat loss are closely related in HIV patients on HAART

CROI: HEPATITIS COINFECTION

• Low dose 200/100 IDV/RTV managed by TDM in substudy of co-infected

patients

• 12-week response predicts which HIV-HCV coinfected patients will not

benefit from continued PEG interferon/ribavirin

• Pegylated interferon associated with eye disorders

CROI: RESISTANCE

• Nevirapine resistance – the cautionary tales continue

TREATMENT ACCESS

• Global Fund gives $210 million for treatment in Thailand

• Anti-HIV combination drug for Indonesia

• Indian generic drug maker Ranbaxy Laboratories to launch own-brand

abacavir

• Roche to sell nelfinavir, saquinavir at cost to least-developed nations

• South Africa appoints another dissident

IMMUNOLOGY 32

• US implementation of large-scale smallpox vaccination plan has special

implications for people with HIV

OTHER NEWS

• UK HIV new cases at record high

• Trizivir-only arm closed in PI-sparing, naïve therapy trial

• Reduced testosterone levels in HIV-positive women

• Fosamprenavir expanded access available in UK

• European approval of adefovir for hepatitis B

• European activists highlight importance of gender based research: women

with HIV suffer differently

• Roche prices enfuvirtide (T-20) at ¤18,980 a year – making it the most

expensive HIV drug yet

• European positive opinion for tenofovir for first line therapy

• Vaxgen announces disappointing results from first large international

vaccine trial

• GMHC criticises Vaxgen for obfuscation of trial results

• Antibiotic-resistant skin infections spreading among gay men, also in

prisons

ON THE WEB

• Further Glasgow and Retrovirus reports

• Medscape: articles in full from AIDS, Journal AIDS etc

• Contents of newsletters now online: Beta, IAPAC, amfAR Insider, PRN

Notebook, GMHC Treatment Issues

• New HIVinSite Knowledge Base chapters: Molecular insights into HIV

biology; Surgery in patients with HIV; HIV

transmission and prevention in prisons; Epidemiology of HIV/AIDS in the

United States; Coinfection with Hepatitis

viruses and HIV

• HHS clinical guide on palliative care of HIV/AIDS patients

PUBLICATIONS AND SERVICES FROM i-BASE

Best Regards,

IT Manager

HIV i-Base